Rosenberg Steven A, Yang James C, Restifo Nicholas P
Surgery Branch of the Center for Cancer Research at the National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502 Bethesda, Maryland 20892-1502, USA.
Nat Med. 2004 Sep;10(9):909-15. doi: 10.1038/nm1100.
Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.
在过去十年中，肿瘤免疫学领域取得了巨大进展，但对当前可用癌症疫苗方法临床应用的乐观态度更多地基于替代终点而非临床肿瘤消退。在我们对440名患者的癌症疫苗试验中，客观缓解率很低（2.6%），与其他人获得的结果相当。我们在此讨论癌症疫苗试验的结果，并强调在临床前和临床模型中介导癌症消退的替代策略。
